Prostate Cancer
Physician Perception of Grade Group 1 Prostate Cancer.
January 25, 2024
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
January 24, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
January 24, 2024
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
January 24, 2024
Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer.
January 24, 2024
Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer.
January 24, 2024
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.
January 24, 2024
Functional Outcomes After Localized Prostate Cancer Treatment
January 23, 2024
The effect of limited english proficiency on prostate-specific antigen screening in American men.
January 23, 2024
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET.
January 23, 2024
Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review.
January 23, 2024
Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis.
January 23, 2024